Role of cyclic GMP-inhibitable phosphodiesterase and nitric oxide in the beta adrenoceptor control of renin secretion

Journal of Pharmacology and Experimental Therapeutics

Volumn 278, Issue 2, 1996, Pages 793-799

  Chiu, Terence ^a   Reid, Ian A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP; CYCLIC GMP; ISOPRENALINE; MILRINONE; N(G) METHYLARGININE; NITRIC OXIDE; PHENYLEPHRINE; PHOSPHODIESTERASE; RENIN;

ANIMAL EXPERIMENT; ARTICLE; BETA ADRENERGIC STIMULATION; DRUG EFFECT; ENZYME INHIBITION; JUXTAGLOMERULAR CELL; MALE; NONHUMAN; PHOSPHATE METABOLISM; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; RABBIT; RENIN RELEASE;

ANIMALS; BLOOD PRESSURE; CYCLIC GMP; HEART RATE; MALE; MILRINONE; NITRIC OXIDE; PHOSPHODIESTERASE INHIBITORS; PYRIDONES; RABBITS; RENIN;

EID: 0030433051     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. BACHMANN, S AND MUNDEL, P: Nitric oxide in the kidney: synthesis, localization and function. Am. J. Kidney Dis. 24: 112-129, 1994.
2. BEAVO, J. A. AND REIFSNYDER, D. H.: Primary sequence of cyclic nucleotide phosphodiesterase isozymes and the design of selective inhibitors. T.I.P.S 11: 150-155, 1990.
3. BURTON, G. A., MACNEIL, S., DE JONGE, A. AND HAYLOR, J: Cyclic GMP release and vasodilation induced by EDRF and atrial natriuretic factor in the isolated perfused kidney of the rat. Br. J. Pharmacol. 99: 364-368, 1990.
4. CHIU, N., PARK, I. AND REID, I. A.: Stimulation of renin secretion by the phosphodiesterase IV inhibitor rolipram. J. Pharmacol. Exp. Ther. 276: 1073-1077, 1996.
5. CODY, R. J., KUBO, S. H., COVIT, A. B., MULLER, F. B., RUTMAN, H., LEONARD, D. LABAGH, J. H., FELDSCHUH, J. AND PREIBISZ, J: Regional blood flow and neurohormonal responses to milrinone in congestive heart failure. Clin. Pharmacol. Ther. 39: 128-135, 1986.
6. CONTI, M., NEMOZ, G., SETTE, C. AND VICINI, E: Recent progress in understanding the hormonal regulation of phosphodiesterases. Endocrine Rev. 16: 370-389, 1995.
7. DAVIS, J. O. AND FREEMAN, R. H.: Mechanisms regulating renin release. Physiol. Rev. 56: 1-56, 1976.
8. EDWARDS, R. M., PULLEN, M. AND NAMBI, P: Activation of endothelin ETB receptors increases glomerular cGMP via an L-arginine-dependent pathway. Am. J. Physiol. 263: F1020-F1025, 1992.
9. GARDES, J., POUX, J-M., GONZALEZ, M-F., ALHENC-GELAS, F. AND MENARD, J: Decreased renin release and constant kallikrein secretion after injection of L-NAME in isolated perfused rat kidney. Life Sci. 50: 987-993, 1992.
10. GLANTZ, S. A. AND SLINKER, B. K.: Primer of Applied Regression and Analysis of Variance. New York, McGraw-Hill, Inc., 1990.
11. HARRISON, S. A., REIFSNYDER, D. H., GALLIS, B., CADD, G. G. AND BEAVO, J. A.: Isolation and characterization of bovine cardiac muscle cGMP-inhibited phosphodiesterase: a receptor for new cardiotonic drugs. Mol. Pharmacol. 29: 506-514, 1986.
12. HAYNES, J., KITHAS, P. A., TAYLOR, A. E. AND STRADA, S. J.: Selective inhibition of cGMP-inhibitable cAMP phosphodiesterase decreases pulmonary vasoreactivity. Am. J. Physiol. 261: H487-H492, 1991.
13. HEUZE-JOUBERT, I., MENNECIER, P., SIMONET, S., LAUBIE, M. AND VERBEUREN, T. J.: Effect of vasodilators, including nitric oxide, on the release of cGMP and cAMP in the isolated perfused rat kidney. Eur. J. Pharmacol. 220: 161-171, 1992.
14. JAFRI, S. M., REDDY, B. R., BUDZINSKI, D., GOLDBERG, A. D., PILLA, A. AND LEVINE, T. B.: Acute neurohormonal and hemodynamic response to a new peak III phosphodiesterase inhibitor (ICI 153,110) in patients with chronic heart failure. J. Cardiovasc. Pharmacol. 16: 360-366, 1990.
15. JOHNSON, R. A. AND FREEMAN, R. H.: Pressure natriuresis in rats during blockade of the L-arginine/nitric oxide pathway. Hypertension 19: 333-338, 1992.
16. JOHNSON, R. A. AND FREEMAN, R. H.: Renin release in rats during blockade of nitric oxide synthesis. Am. J. Physiol. 266: R1723-R1729, 1994.
17. KEETON, T. K. AND CAMPBELL, W. B.: The pharmacologic alteration of renin release. Pharmacol. Rev. 32: 81-227, 1980.
18. KERWIN, J. F. AND HELLER, M: The arginine-nitric oxide pathway: a target for new drugs. Med. Res. Rev. 14: 23-74, 1994.
19. KLABUNDE, R. E., KIMBER, N. D., KUK, J. E. AND HELGREN, M. C., FORSTERMANN U: NG-methyl-L-arginine decreases contractility, cGMP and cAMP in isoproterenol-stimulated rat hearts in vitro. Eur. J. Pharmacol. 223: 1-7, 1992.
20. KURTZ, A., KAISSLING, B., BUSSE, R. AND BAIER, W: Endothelial cells modulate renin secretion from isolated mouse juxtaglomerular cells. J. Clin. Invest. 88: 1147-1154, 1991.
21. MENARD, J. AND CATT, K. J.: Measurement of renin activity, concentration and substrate in rat plasma by radioimmunoassay of angiotensin I. Endocrinology 90: 422-430, 1972.
22. MUNDEL, P., BACHMANN, S., BADER, M., FISCHER, A., KUMMER, W., MAYER, B. AND KRIZ, W: Expression of nitric oxide synthase in kidney macula densa cells. Kidney Int. 42: 1017-1019, 1992.
23. MURALI, S., URETSKY, B. F., VALDES, A. M., KOLESAR, J. A. AND REDDY, B. R.: Acute hemodynamic and hormonal effects of CI-930, a new phosphodiesterase inhibitor, in severe congestive heart failure. Am. J. Cardiol. 59: 1356-1360, 1987.
24. MURRAY, K. J.: Methods in cyclic nucleotide research. In Intracellular Messengers, ed. by A. A. Boulton, G. B. Baker and C. W. Taylor, Humana Press, New Jersey, 1992, pp 313-368.
25. PANG, D. C.: Cyclic AMP and cyclic GMP phosphodiesterases: target for drug development. Drug Dev. Res. 12: 85-92, 1988.
26. REES, D. D., PALMER, RMJ, SCHULZ, R., HODSON, H. F. AND MONCADA, S: Characterization of three inhibitors of endothelial nitric oxide synthase in vitro and in vivo. Br. J. Pharmacol. 101: 746-752, 1990.
27. REID, I. A., BUI, H. AND CHOU, L: Role of nitric oxide in the renin and heart rate responses to beta adrenergic stimulation. Hypertension 23(Suppl. I): I-49-I-53, 1994.
28. REID, I. A. AND CHIU, Y. J.: Nitric oxide and the control of renin secretion. Fundament. Clin. Pharmacol. 9: 309-323, 1995.
29. REID, I. A., MORRIS, B. J. AND GANONG, W. F.: The renin-angiotensin system. Ann. Rev. Physiol. 40: 377-410, 1978.
30. REID, I. A., STOCKIGT, J. R., GOLDFIEN, A. AND GANONG, W. F.: Stimulation of renin secretion in dogs by theophylline. Eur. J. Pharmacol. 17: 325-332, 1972.
31. SCHRICKER, K., RITTHALER, T., KRAMER, B. K. AND KURTZ, A: Effect of endothelium-derived relaxing factor on renin secretion from isolated mouse renal juxtaglomerular cells. Acta Physiol. Scand. 149: 347-354, 1993.
32. SIGMON, D. H., CARRETERO, O. A. AND BEIERWALTES, W. H.: Endothelium-derived relaxing factor regulates renin release in vivo. Am. J. Physiol. 263: F256-F261, 1992.
33. SIRAGY, H. M.: Endothelium-derived relaxing factor modulates renal interstitial cyclic GMP. J. Cardiovasc. Pharmacol. 20: S163-S165, 1992.
34. SUGIOKA, M., ITO, M., MASUOKA, H., ICHIKAWA, K., KONISHI, T., TANAKA, T. AND NAKANO, T: Identification and characterization of isoenzymes of cyclic nucleotide phosphodiesterase in human kidney and heart, and the effects of new cardiotonic agents on these isoenzymes. Arch. Pharmacol. 360: 284-293, 1994.
35. TERADA, Y., TOMITA, K., NONOGUCHI, H. AND MARUMO, F: Polymerase chain reaction localization of constitutive nitric oxide synthase and soluble guanylate cyclase messenger RNAs in microdissected rat nephron segments. J. Clin. Invest. 90: 659-665, 1992.
36. URETSKY, B. F., GENERALOVICH, T., VERBALIS, J. G., VALDES, A. M. AND REDDY, P. S.: Comparative hemodynamic and hormonal response to enoximone and dobutamine in severe congestive heart failure. Am. J. Cardiol. 58: 110-116, 1986.
37. WETZEL, B. AND HAUEL, N: New cardiotonic agents - a promising approach for treatment of heart failure. T.I.P.S. 9: 166-170, 1988.
38. WILCOX, C. S., WELCH, W. J., MURAD, F., GROSS, S. S., TAYLOS, G., LEVI, R. AND SCHMIDT, H. H. H. W: Nitric oxide synthase in macula densa regulates glomerular capillary pressure. Proc. Natl. Acad. Sci. USA 89: 11993-11997, 1992.